Videos

Recommendations for using AR-targeted therapy as an approach when managing patients with metastatic castrate-sensitive prostate cancer.

Caitlin Costello, MD, discusses choosing the optimal first-line therapy for patients with multiple myeloma.

Bassel El-Rayes, MD, reviews the case of a 66-year old man with gastric carcinoma and discusses the disease from diagnosis to unmet needs.

Al B. Benson, MD, discusses recent developments for the treatment of patient with hepatocellular carcinoma with systemic therapy in the first and second line.

The most interesting developments and approvals in breast cancer treatment in the last year and expectations regarding data that will be presented on at the upcoming 2020 San Antonio Breast Cancer Symposium.

Alexander Spira, MD, PhD, shares an important message with community oncologists regarding the treatment of patients with lung cancer.

Roman Perez-Soler, MD, discusses how MET mutations have evolved and impacted the treatment of patients with lung cancer.

Matthew Davids, MD, MMSc, discusses the prognosis expected for patients with mantle cell lymphoma, as well as chronic lymphocytic leukemia, in the relapsed/refractory population.

John O. Mascarenhas, MD, discusses pacritinib for patients with myelofibrosis and thrombocytopenia.

Ryan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.

Petros Grivas, MD, PhD, discusses the phase 3 KEYNOTE-045 trial and the association between gene expression signatures and pembrolizumab in patients with advanced urothelial cancer.

Victor Velculescu, MD, PhD, discusses the key takeaways regarding the use of liquid biopsy to detect cancer and a new cfDNA approach to detect cancer at earlier stages.

Maria E. Cabanillas, MD, discusses the pooled results of 2 larotrectinib trials for patients with advanced or metastatic TRK fusion-positive thyroid cancer.

Nilanjan Ghosh, MD, discusses the effect coronavirus disease 2019 had on using chimeric antigen receptor T-cell therapy to treat patients with diffuse large B-cell lymphoma.

Hope Rugo, MD, discusses her key takeaways in the field of HER2-positive breast cancer.

Brain A. Jonas, MD, discusses the future of treatment for older patients with acute myeloid leukemia, now that the FDA has granted approval to azacitidine plus venetoclax for patients aged 75 years or older.

Dr David Spigel provides information on the PACIFIC trial, including the 4-year update.

Nirav N. Shah, MD, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor T cells in a phase 1 dose escalation and expansion trial for relapsed B cell malignancies.

Benjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.